Sherif Farag, MD
Hematology · Kokomo, INNPI 1699784710
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $41,512 of the $67,503 with a category attached, or 61.5%. 14 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 48.8% of the total. 2025 is the largest year on record at $42,164, 3.9 times the $10,839 reported in 2019.
Across 58 payments — averaging $1163.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$33K
- Sanofi-aventis U.S. LLC$14K
- Jazz Pharmaceuticals Inc.$11K
- Regeneron Healthcare Solutions, Inc.$9K
- Novartis$240
- Gilead$189
- plus $455 from 8 others
Across 98 payments — averaging $8794.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$331K
- Takeda Pharmaceuticals U.S.A., Inc.$246K
- Incyte Corporation$144K
- E.r. Squibb & Sons, L.L.C.$69K
- National Marrow Donor Program$35K
- Merck$23K
- plus $13K from 1 others
What the payments were for
- Consulting fees$18,76628%
- Speaking & faculty fees$41,51261%
- Travel & lodging$5,0327%
- Food & beverage$2,1943%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 15 | $32,940 |
| Sanofi-aventis U.S. LLC | 8 | $13,850 |
| Jazz Pharmaceuticals Inc. | 15 | $10,766 |
| Regeneron Healthcare Solutions, Inc. | 4 | $9,064 |
| Novartis | 4 | $240 |
| Gilead | 3 | $189 |
| National Marrow Donor Program | 1 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $110 |
| Tempus AI, Inc | 1 | $61 |
| Iovance Biotherapeutics, Inc. | 1 | $39 |
| AbbVie | 2 | $32 |
| Ipsen Biopharmaceuticals, Inc | 1 | $21 |
| Johnson & Johnson | 1 | $21 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in Indianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 30 | $469,374 |
| RezurockBelumosudil Mesylate | 13 | $233,627 |
| EliquisApixaban | 27 | $20,037 |
| Sirolimus | 17 | $2,882 |
| Acyclovir | 115 | $2,426 |
| Fluconazole | 17 | $1,192 |
| Potassium Chloride | 16 | $730 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 56 | $362 |
| Pantoprazole Sodium | 13 | $128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sanofi-aventis U.S. LLCRezurock | $13,850 | $233,62713 claims |
| PfizerEliquis | $15 | $20,03727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Indianaon file to place this against a meaningful peer group, so we don't.
Other hematology in Kokomo
- Rafat AbonourIndianapolis$712K
- Luke AkardIndianapolis$358K
- Felix MensahIndianapolis$152K
- Brandon HardestyIndianapolis$72K
- Lalitha NayakIndianapolis$11K
- Kushal NahaFort Wayne$7K
- Fatemeh Ardeshir LarijaniIndianapolis$3K
- Mark DaytonBloomington$1K
- Pavan RavellaLafayette$1K
- Thomas JonesLafayette$591
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.